Detection of Acute Renal Failure Using Hospital Coding Data (IRA-PMSI)
Acute Kidney Injury and Drug-related Acute Kidney Injury : Use of Hospital Coding Data for Their Identification
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Sophie LIABEUF, Pr
- Phone Number: 03 22 08 79 95
- Email: Liabeuf.sophie@chu-amiens.fr
Study Contact Backup
- Name: Valérie GRAS, MD
- Phone Number: 03 22 08 70 96
- Email: gras.valerie@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80480
- CHU Amiens
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients over > = 18 years old
- Patients hospitalized at the CHU Amiens Picardie during 6 months
- patients for which at least two plasma creatinine measurements were taken during the hospitalization
Exclusion Criteria:
- Patients under <18 years old
- Patients on dialysis for chronic renal failure
- Hospitalization for a kidney transplant
- Postpartum AKI
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
identification of AKIs by codes in the PMSI database
Time Frame: two years
|
two years
|
|
identification of drug-induced AKIs by codes in the PMSI database
Time Frame: two years
|
two years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Variation of performance of the codes according to the characteristics of the AKI
Time Frame: two years
|
two years
|
|
|
Variation of performance of the codes according to KDIGO grade
Time Frame: two years
|
two years
|
|
|
Variation of performance of the codes according to hospitalization service
Time Frame: two years
|
two years
|
|
|
Identification of the type of drugs involved in drug-induced AKI
Time Frame: two years
|
two years
|
|
|
incidence of drug-induced AKI
Time Frame: two years
|
incidence of drug-induced AKI (community-based and hospital-induced AKI (AKI-AH))
|
two years
|
|
Identification of AKI Risk factors
Time Frame: two years
|
two years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PI2020_843_0018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.